JointHealth
français
Arthritis Medications Report Card
How does your province measure up?

The JointHealth™ Arthritis Medications Report Card is designed to help Canadians evaluate how their province measures up in terms of providing reimbursement access to medications approved for autoimmune (like rheumatoid arthritis) arthritis treatment.

Depending on where they live, Canadians living with an autoimmune arthritis may have fewer treatment options or have to “jump through more hoops” to qualify for reimbursement for the medication prescribed for them by their rheumatologist or other specialist.

The JointHealth™ Arthritis Medications Report Card highlights this inequality of treatment and now tracks three classes of medications used to treat auto-immune forms of arthritis: Biologic Response Modifiers (Biologics), subsequent entry biologics (SEBs) and Targeted small molecule medications (TSMMs).

If your province doesn’t measure up, ACE encourages you to write and speak to your elected provincial or federal representative about the lack of equitable reimbursement access and patient/physician choice in treating auto-immune forms of arthritis.

printer-friendly printer-friendly
Medications Chart : Updated December 2016
1st : Québec   (1st in 2014, 3rd in 2013, 2nd in 2012, 2nd in 2011)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A This is a new medical term used to describe early disease not yet visible on X-ray. Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A Declined N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A Under Review N/A
secukinumab (Cosentyx®) N/A Under Review N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A Listed—CBC N/A N/A N/A
SEB infliximab (Inflectra®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A Declined N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A
1st : Saskatchewan   (1st in 2014, 1st in 2013, 4th in 2012, 2nd in 2011)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A This is a new medical term used to describe early disease not yet visible on X-ray. Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A Declined N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A Listed—CBC N/A
secukinumab (Cosentyx®) N/A Under Review N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A Listed—CBC N/A N/A N/A
SEB infliximab (Inflectra®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A
3rd : Ontario   (1st in 2014, 1st in 2013, 1st in 2012, 5th in 2011)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A This is a new medical term used to describe early disease not yet visible on X-ray. Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A Declined N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®) Listed—ORC Listed—ORC Listed—ORC Listed—ORC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A Listed—CBC N/A
secukinumab (Cosentyx®) N/A Under Review N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A Declined N/A N/A N/A
SEB infliximab (Inflectra®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A
4th : British Columbia   (1st in 2014, 3rd in 2013, 2nd in 2012, 1st in 2011)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A This is a new medical term used to describe early disease not yet visible on X-ray. Listed—CBC N/A N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A Declined N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®) Listed—ORC Listed—ORC N/A Listed—ORC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A Listed—CBC N/A
secukinumab (Cosentyx®) N/A Under Review N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A Declined N/A N/A N/A
SEB infliximab (Inflectra®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A
4th : Nova Scotia   (5th in 2014, 7th in 2013, 8th in 2012, 8th in 2011)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A This is a new medical term used to describe early disease not yet visible on X-ray. Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A Under Review N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®) Listed—ORC Listed—ORC N/A Listed—ORC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A Listed—CBC N/A
secukinumab (Cosentyx®) N/A Under Review N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A Under Review N/A N/A N/A
SEB infliximab (Inflectra®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A
4th : New Brunswick   (8th in 2014, 7th in 2013, 6th in 2012, 5th in 2011)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A This is a new medical term used to describe early disease not yet visible on X-ray. Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A Under Review N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®) Listed—ORC Listed—ORC N/A Listed—ORC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A Listed—CBC N/A
secukinumab (Cosentyx®) N/A Under Review N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A Under Review N/A N/A N/A
SEB infliximab (Inflectra®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A
7th : Alberta   (7th in 2014, 6th in 2013, 5th in 2012, 4th in 2011)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A This is a new medical term used to describe early disease not yet visible on X-ray. Listed—ORC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A Declined N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®) Listed—ORC Listed—ORC N/A Listed—ORC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A Listed—CBC N/A
secukinumab (Cosentyx®) N/A Under Review N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A Under Review N/A N/A N/A
SEB infliximab (Inflectra®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A
8th : Prince Edward Island   (8th in 2014, 7th in 2013, 10th in 2012, 8th in 2011)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A This is a new medical term used to describe early disease not yet visible on X-ray. Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A Under Review N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®) Listed—ORC Listed—ORC N/A Listed—ORC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A Listed—CBC N/A
secukinumab (Cosentyx®) N/A Under Review N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A Under Review N/A N/A N/A
SEB infliximab (Inflectra®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Under Review N/A N/A N/A N/A N/A N/A
9th : Newfoundland and Labrador   (11th in 2014, 10th in 2013, 6th in 2012, 5th in 2011)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A This is a new medical term used to describe early disease not yet visible on X-ray. Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A Under Review N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®) Listed—ORC Listed—ORC N/A Declined N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A Listed—CBC N/A
secukinumab (Cosentyx®) N/A Under Review N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A Under Review N/A N/A N/A
SEB infliximab (Inflectra®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Under Review N/A N/A N/A N/A N/A N/A
10th : Manitoba   (5th in 2014, 5th in 2013, 11th in 2012, 11th in 2011)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A This is a new medical term used to describe early disease not yet visible on X-ray. Under Review In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A Under Review N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®) Listed—CBC Listed—CBC Unknown Listed—CBC N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®) Listed—ORC Listed—ORC N/A Listed—ORC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A Listed—CBC N/A
secukinumab (Cosentyx®) N/A Under Review N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A Under Review N/A N/A N/A
SEB infliximab (Inflectra®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A
11th : NIHB*   (8th in 2014, 10th in 2013, 8th in 2012, 8th in 2011)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A This is a new medical term used to describe early disease not yet visible on X-ray. Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A Under Review N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®) Listed—CBC Listed—CBC Listed—CBC Listed—CBC N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®) Listed—CBC Declined N/A Declined N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A Under Review N/A
secukinumab (Cosentyx®) N/A Under Review N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A Under Review N/A N/A N/A
SEB infliximab (Inflectra®) Listed—CBC Under Review N/A Under Review N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A
12th : Yukon   (12th in 2014, 12th in 2013, 12th in 2012, 12th in 2011)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) N/A N/A This is a new medical term used to describe early disease not yet visible on X-ray. Under Review In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC Under Review Listed—CBC N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A Under Review N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®) Listed—CBC Listed—CBC Under Review Listed—CBC N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®) Listed—ORC Listed—ORC N/A Listed—ORC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A Under Review N/A
secukinumab (Cosentyx®) N/A Under Review N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A Under Review N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A Under Review N/A N/A N/A
SEB infliximab (Inflectra®) Listed—CBC Listed—CBC N/A Listed—CBC N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A

About the report card:
Arthritis Consumer Experts graded each of the provinces by assigning a score based upon number of medications listed, number under review, and number of declined listings. In some cases, information was unavailable from a province or territory's website. This lack of transparency was reflected in grade assignments.

Because provincial formularies change frequently, we encourage you to contact the Ministry of Health in your province with questions you may have about medication listings of concern to you.

Definitions

Declined: The formulary does not reimburse patients prescribed this medication.
In Trials: This medication is undergoing testing for use in treating this disease type.
Listed—CBC: Each province and territory has a process by which medications that are not normally included in the provincial, territorial or federal drug benefit lists are covered (or reimbursed). Approval of this drug is granted on a case-by-case basis.
Listed—ORC: The medication is listed, but the criteria are not supported by medical evidence. Arthritis Consumer Experts considers these overly restrictive criteria (ORC) unacceptable.
N/A: (Not Applicable) No Notice of Compliance (or NOC) has been issued for this medication for this form of arthritis.
Under Review: This drug has been approved by Health Canada for this disease type and the province is considering whether patients should be reimbursed for it.
Unknown: There is no public information available.
CDR: The Common Drug Review (CDR) is part of the Canadian Agency for Drugs and Technologies in Health. The Common Drug Review (CDR) conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Québec). (http://cadth.ca/index.php//cdr)


* Note: People living in the Northwest Territories and Nunavut, who do not have private health insurance, have coverage for those drugs listed on the federal Non-Insured Health Benefits (NIHB) Formulary.

Disclaimer: The material contained in this or any other ACE publication is provided for general information only. It should not be relied on to suggest a course of treatment for a particular individual or as a substitute for consultation with qualified health professionals who are familiar with your individual medical needs. If you have any healthcare related questions or concerns, you should contact your physician. Never disregard medical advice or delay in seeking it because of something you have read in any ACE publication.